Treasurer of the State of North Carolina Has $68.06 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Treasurer of the State of North Carolina increased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 261,132 shares of the medical research company's stock after acquiring an additional 1,291 shares during the quarter. Treasurer of the State of North Carolina's holdings in Amgen were worth $68,061,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Centricity Wealth Management LLC acquired a new stake in shares of Amgen during the 4th quarter valued at $25,000. Ritter Daniher Financial Advisory LLC DE lifted its position in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after acquiring an additional 51 shares during the last quarter. Synergy Investment Management LLC bought a new stake in Amgen during the 4th quarter valued at approximately $34,000. Atala Financial Inc acquired a new stake in shares of Amgen in the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in Amgen in the 4th quarter worth $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Piper Sandler Companies reaffirmed an "overweight" rating and issued a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Royal Bank of Canada reiterated an "outperform" rating and issued a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Truist Financial dropped their target price on shares of Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a research report on Wednesday, January 8th. Finally, Citigroup reissued a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $314.91.

Remove Ads

Amgen Stock Performance

AMGN traded up $0.76 on Tuesday, reaching $294.68. The company had a trading volume of 1,221,575 shares, compared to its average volume of 2,772,608. The company's fifty day moving average is $304.05 and its 200 day moving average is $294.91. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock has a market cap of $158.43 billion, a P/E ratio of 39.03, a P/E/G ratio of 2.63 and a beta of 0.59. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.23%. The ex-dividend date is Friday, May 16th. Amgen's payout ratio is currently 126.09%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 in the last ninety days. 0.69% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.